Humana Inc. (HUM) Up 7.0% — Time to Press the Buy Button?
Humana Inc. (HUM) is surging in Friday's session, up 6.97%, or $26.51, and was last trading at $406.83 from the prior close of $380.32. The rally has quickly brought the health insurance giant back into the upper end of its range. Shares now sit roughly 5.1% below the 52-week high of $428.88, set on July 16, 2026, a level within reach if buyers keep up the pace.
Volume so far stands at about 487,630 shares, roughly 38% of the 90-day average of 1,273,437. The session is still open, so turnover has room to build as the day continues.
Why Humana Inc. Price is Moving Higher
The clearest catalyst for Friday's surge is a major call from Barclays. Analyst Andrew Mok upgraded Humana to Overweight from Equal Weight and raised his price target to $515 from $407, which implies roughly 25% upside from the stock's trading level near $411. Barclays called the setup "particularly compelling" and said it has greater confidence that Humana's Medicare Advantage Star Ratings will improve. That thesis matters for Humana's earnings. Higher Star Ratings unlock larger government bonus payments, and those payments feed directly into insurance margins. A $108 increase in the price target gives investors a concrete basis for revaluing the stock, and the market is responding decisively.
The upgrade builds on a solid Q2 report released July on 29. Humana posted adjusted EPS of $7.61 against the $7.22 consensus, a $0.39 beat. Revenue reached $40.87 billion versus $40.61 billion expected. Top-line growth was strong, with revenue up 26.2% year over year from $32.39 billion and adjusted EPS up 21.4% from $6.27. Those gains show a membership and premium base that continues to scale at a rapid clip.
The quarter did carry some caveats, which helps explain why Barclays' view is carrying so much weight. Management maintained its adjusted 2026 EPS guidance of $9.00. However, it cut GAAP guidance to $6.52 from $8.36, citing non-cash charges. The 91.2% insurance benefit ratio came in line with expectations. With medical costs holding steady rather than improving, Star Ratings gains and margin recovery are the main upside drivers, and today's upgrade puts both firmly in focus.
What is the Humana Inc. Rating - Should I Buy?
Weiss Ratings assigns HUM a C rating. Current recommendation is Hold. That rating reflects a company with real balance sheet strength and improving momentum, offset by thin profitability and a stock that has moved sharply in both directions.
The strongest element of the profile is the Excellent Solvency Index. That financial footing gives Humana room to absorb the medical cost swings that have unsettled managed care over the past two years. ROE of 6.89% supports a Good Efficiency Index. The figure is respectable for an insurer rebuilding margins after an elevated benefit-cost cycle, and it leaves meaningful upside if Star Ratings bonuses flow back into earnings.
The Weak Growth Index tells a more complicated story. Revenue growth of 26.18% is impressive on its own. Profit growth has not kept pace, however, and a profit margin of just 0.87% shows how little of that expanding premium base is reaching the bottom line. The GAAP guidance cut to at least $6.52 adds to that pressure. The forward P/E of 36.00 also looks elevated for a managed care company, so the valuation depends on a real margin recovery. EPS of $10.57 provides a baseline, but investors will want evidence that earnings can climb from here.
On the market side, the Fair Total Return Index and Weak Volatility Index point to uneven performance and sharp price swings, and today's nearly 7% jump is one example. Within the Health Care sector, Humana sits alongside Abbott Laboratories (ABT, C) and Stryker Corporation (SYK, C), ranks ahead of UnitedHealth Group Incorporated (UNH, C-), and trails Medtronic plc (MDT, C+). Those comparisons put HUM in the middle of the large-cap pack, with a Star Ratings improvement as a possible path to a higher grade.
About Humana Inc.
Humana Inc. (HUM) is a Health Care company and one of the largest health insurers in the United States. Its business centers on government-sponsored health programs, most notably Medicare Advantage. That focus makes Humana one of the purest large-cap plays on the growing senior population and on the shift of Medicare beneficiaries toward private plans.
Beyond Medicare Advantage, Humana offers stand-alone prescription drug plans, Medicaid managed care, and specialty coverage. It also runs a growing health services operation that includes primary care clinics focused on seniors, home health, and pharmacy services. This integrated model lets Humana coordinate care across settings, manage chronic conditions more closely, and capture value that pure insurers often cede to outside providers.
Humana's competitive advantages come from its scale in the senior market, long-standing relationships with the Centers for Medicare & Medicaid Services, and deep experience managing high-need populations. Its investments in value-based primary care and care coordination are built to improve patient outcomes and quality scores. Those scores feed directly into Star Ratings and the bonus payments that come with them, which gives Humana a structural reason to keep investing in care quality.
Investor Outlook
Humana (HUM) carries a Weiss Rating of C (Hold). The Barclays upgrade adds a fresh, forward-looking argument for the stock as Star Ratings confidence rises. Investors should watch whether shares can challenge the $428.88 52-week high, how upcoming Star Ratings announcements shape bonus payment expectations, and whether margins improve enough to lift the Weak Growth Index. See full rankings of all C-rated Health Care stocks inside the Weiss Stock Screener.
--